Novo Nordisk Total Long Term Liabilities 2012-2026 | NVO

Novo Nordisk total long term liabilities for the quarter ending March 31, 2026 were $20.514B, a 26.97% increase year-over-year.

  • Novo Nordisk total long term liabilities for 2025 were $20.166B, a 32.73% increase from 2024.
  • Novo Nordisk total long term liabilities for 2024 were $15.193B, a 173.42% increase from 2023.
  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.

Novo Nordisk Total Long Term Liabilities 2012-2026 | NVO

  • Novo Nordisk total long term liabilities for 2025 were $20.166B, a 32.73% increase from 2024.
  • Novo Nordisk total long term liabilities for 2024 were $15.193B, a 173.42% increase from 2023.
  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B